Research programme: antisense oligonucleotides - EpiGenesis/Idera Pharmaceuticals

Drug Profile

Research programme: antisense oligonucleotides - EpiGenesis/Idera Pharmaceuticals

Alternative Names: RASONs - EpiGenesis/Hybridon; Respirable antisense oligonucleotides - EpiGenesis/Hybridon

Latest Information Update: 02 Apr 2008

Price : $50

At a glance

  • Originator EpiGenesis Pharmaceuticals; Idera Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Respiratory tract disorders

Most Recent Events

  • 13 Sep 2005 Hybridon is now called Idera Pharmaceuticals
  • 31 Dec 2004 This programme is still in active development
  • 23 Apr 2001 Preclinical development for Respiratory tract disorders in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top